NUCLIDIUM AG Raises $84M in Series B Funding to Revolutionize Precision Oncology with Copper-Based Radiopharmaceuticals

Nuclidium AG is thrilled to announce a major milestone in our mission to transform precision oncology, as we have successfully raised $84,000,000 in new funding. This significant capital injection empowers us to accelerate the development of our best-in-class copper-based radiopharmaceuticals, setting a new standard in targeted cancer treatment and diagnosis. At the heart of our innovation is the CuTrace™ platform, which uniquely combines copper radiometals with highly specific cancer-targeting molecules to rapidly create novel therapeutic and diagnostic programs. With this latest funding, we will expand our research and development capabilities, optimize manufacturing processes, and broaden our product portfolio to better serve healthcare providers and patients alike. Our differentiated “diagnostic to therapeutic” approach is driving clinical advancements by leveraging the unique properties of copper to offer improved safety and efficacy profiles, along with enhanced cost-effectiveness for hospitals and patients. This funding round marks a pivotal moment as it not only validates the potential of our innovative solutions but also enables us to overcome supply limitations in manufacturing and distribution. By doing so, we ensure that cutting-edge treatments become more accessible to medical facilities worldwide, ultimately offering hope to countless cancer patients. At Nuclidium, our diverse and interdisciplinary team is dedicated to reshaping the future of precision radio-oncology. With innovation at our core, we are committed to de-risking our development pathway and delivering measurable benefits for the medical community. This new funding is a strong vote of confidence in our vision, and we look forward to driving forward transformative changes that will redefine cancer care on a global scale.